Home infusion costs less, improves outcomes, according to Option Care study
SAN ANTONIO – Patients treated with immunoglobulin therapy at home with a high level of clinical oversight by Option Care had better outcomes than others receiving the therapy, according to a recent study. “We found that the provision of comprehensive and consistent care in a patient’s own home does indeed lead to better outcomes,” said Jordan Orange, M.D., Ph.D., lead investigator of the study and a professor at Baylor College of Medicine in Houston. “And an added benefit was that it was actually more cost effective.” The study found that costs per year for Option Care patients totaled $112,700 compared to $120,500 for patients from the control group. The findings were presented this week at the American College of Allergy, Asthma and Immunology (ACAAI) Annual Scientific Meeting. Formerly Walgreens Infusion Services, Option Care offers home and alternate treatment sites infusion services.